Retraction
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine
Paper Information
Record ID:
42788
Journal:
Publication Date:
December 08, 2003
Retraction Date:
February 16, 2023
(2.8 years years ago)
Subjects:
Country:
🇺🇸 United StatesArticle Type:
Publisher:
Springer - Nature Publishing Group
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (230)
230
Total Citations4
Post-Retraction(1.7%)
226
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
1
Within 30 days
2
Within 1 year
1
After 2+ years
869
Days since retraction (latest)
A phase 1/1B trial of ADI‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma
Maeve A. Lowery, Kenneth H. Yu, David P. Kelsen et al. (16 authors)
Cancer
Open Access
Published: Aug 2017
69 citations
69 citations
2008 days before retraction
<i>De Novo</i> Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer
Saber Tadros, Surendra K. Shukla, Ryan J. King et al. (13 authors)
Cancer Research
Open Access
Published: Aug 2017
181 citations
181 citations
2010 days before retraction
Suppression of pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer to gemcitabine and 5FU, and inhibits the formation of pancreatic cancer stem like cells
Jae Hee Cho, Sun A Kim, Soo Been Park et al. (5 authors)
Oncotarget
Open Access
Published: Jul 2017
18 citations
18 citations
2035 days before retraction
Integrated analysis of mRNA and miRNA expression profiles in pancreatic ductal adenocarcinoma
Hongwei Sun, Liang Zhao, Kehua Pan et al. (6 authors)
Oncology Reports
Open Access
Published: Mar 2017
13 citations
13 citations
2155 days before retraction
Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
Min Tu, Haifeng Li, Nan Lv et al. (12 authors)
Molecular Cancer
Open Access
Published: Mar 2017
26 citations
26 citations
2158 days before retraction
Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK
Girijesh Kumar Patel, Mohammad Aslam Khan, Arun Bhardwaj et al. (9 authors)
British Journal of Cancer
Open Access
Published: Feb 2017
234 citations
234 citations
2206 days before retraction
Enzalutamide inhibits proliferation of gemcitabine-resistant bladder cancer cells with increased androgen receptor expression
Koji Kameyama, Kengo Horie, Kosuke Mizutani et al. (10 authors)
International Journal of Oncology
Open Access
Published: Nov 2016
25 citations
25 citations
2275 days before retraction
COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value
Yuanfeng Gao, Xiao‐Yuan Mao, Tao Zhu et al. (12 authors)
Oncotarget
Open Access
Published: Sep 2016
71 citations
71 citations
2345 days before retraction
TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3
Rachel Hesler, Jennifer J. Huang, Mark D. Starr et al. (9 authors)
Carcinogenesis
Open Access
Published: Sep 2016
82 citations
82 citations
2353 days before retraction
Human pancreatic cancer progression: an anarchy among CCN-siblings
Sushanta K. Banerjee, Gargi Maity, Inamul Haque et al. (9 authors)
Journal of Cell Communication and Signaling
Open Access
Published: Aug 2016
21 citations
21 citations
2372 days before retraction
A Comprehensive Overview of Mouse Models in Oncology
Divya Vats
Methods and principles in medicinal chemistry
Published: Aug 2016
2376 days before retraction
Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640
Clayton S. Lewis, Christina Voelkel‐Johnson, Charles D. Smith
Oncotarget
Open Access
Published: Aug 2016
42 citations
42 citations
2383 days before retraction
MEK inhibition in pancreas cancer
Francesca Vena
Doctoral thesis, UCL (University College London).
Published: Apr 2016
2485 days before retraction
Paper citing RNA interference targeting the M2 subunit of ribon...
Unknown Authors
Unknown Journal
Published: Feb 2016
2555 days before retraction
Imaging-guided delivery of RNAi for anticancer treatment
Junqing Wang, Peng Mi, Ge Lin et al. (6 authors)
Advanced Drug Delivery Reviews
Open Access
Published: Jan 2016
110 citations
110 citations
2582 days before retraction
Efficacy and Mechanism of Action of a Novel Class of Antic-Cancer Drugs
Claudia Terán
Unknown Journal
Published: Jan 2016
2603 days before retraction
Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2′, 2′-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity
Youssef W. Naguib, Dharmika S.P. Lansakara-P, Laura M. Lashinger et al. (10 authors)
Neoplasia
Open Access
Published: Jan 2016
16 citations
16 citations
2603 days before retraction
Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer.
Vince Kornél Grolmusz, Katalin Karászi, Tamás Micsík et al. (15 authors)
PubMed
Published: Jan 2016
63 citations
63 citations
2603 days before retraction
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Yoav Binenbaum, Shorook Na’ara, Ziv Gil
Drug Resistance Updates
Published: Nov 2015
361 citations
361 citations
2664 days before retraction
MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways
Adriana Estrada‐Bernal, Moumita Chatterjee, S. Jaharul Haque et al. (9 authors)
Cell Cycle
Open Access
Published: Oct 2015
60 citations
60 citations
2668 days before retraction
MEK Inhibitor GSK1120212-Mediated Radiosensitization of Pancreatic Cancer Cells Involves Inhibition of DNA Double-Strand Break Repair Pathways
Terence M. Williams, Ana P. Estrada-Florez, Moumita Chatterjee et al. (6 authors)
International Journal of Radiation Oncology*Biology*Physics
Published: Oct 2015
4 citations
4 citations
2679 days before retraction
Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma
Zejun Fang, Rui Song, Chaoju Gong et al. (13 authors)
Tumor Biology
Published: Oct 2015
9 citations
9 citations
2687 days before retraction
Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway
Takushi Namba, Rika Kodama, S Moritomo et al. (5 authors)
Cell Death and Disease
Open Access
Published: Jun 2015
71 citations
71 citations
2793 days before retraction
Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells
Dong Joon Kim, Young Soo Park, Mingu Kang et al. (13 authors)
Experimental Cell Research
Published: Jun 2015
51 citations
51 citations
2795 days before retraction
Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy
Xin Dai, Ying Jiang, Chalet Tan
PLoS ONE
Open Access
Published: May 2015
27 citations
27 citations
2843 days before retraction
Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma
Kazuki Iwamoto, Koh‐ichi Nakashiro, Hiroshi Tanaka et al. (5 authors)
International Journal of Oncology
Open Access
Published: Mar 2015
21 citations
21 citations
2908 days before retraction
Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells
Yehua Shen, Yan Pan, Litao Xu et al. (8 authors)
Tumor Biology
Published: Feb 2015
30 citations
30 citations
2912 days before retraction
RECQL1 and WRN DNA repair helicases: potential therapeutic targets and proliferative markers against cancers
Kazunobu Futami, Yasuhiro Furuichi
Frontiers in Genetics
Open Access
Published: Jan 2015
27 citations
27 citations
2960 days before retraction
Utilization of a PNA-peptide conjugate to induce a cancer protease-responsive RNAi effect
Eun Kyung Lee, Chan Woo Kim, Hiroyuki Kawanami et al. (7 authors)
RSC Advances
Published: Jan 2015
1 citation
1 citation
2968 days before retraction
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer
Rouzbeh Daylami, Diego Muilenburg, Subbulakshmi Virudachalam et al. (4 authors)
Journal of Experimental & Clinical Cancer Research
Open Access
Published: Dec 2014
35 citations
35 citations
2999 days before retraction
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy
Hui Zhao, Huawei Zhang, Yonghai Du et al. (4 authors)
Tumor Biology
Published: Sep 2014
33 citations
33 citations
3074 days before retraction
Deoxycytidine Kinase Expression Underpins Response to Gemcitabine in Bladder Cancer
Martin Kerr, Helen E. Scott, Blaž Grošelj et al. (7 authors)
Clinical Cancer Research
Open Access
Published: Sep 2014
27 citations
27 citations
3075 days before retraction
Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers
Hang Zhang, Xiyong Liu, Charles Warden et al. (10 authors)
BMC Cancer
Open Access
Published: Sep 2014
54 citations
54 citations
3080 days before retraction
Investigation of approaches for overcoming chemoresistance in pancreatic cancer
Sau Wai Hung
Unknown Journal
Published: Aug 2014
3121 days before retraction
SMOC1-induced osteoblast differentiation involves enhanced proliferation of human bone marrow mesenchymal stem cells
Young‐Ae Choi, Dong-Sung Kim, Hong‐In Shin et al. (4 authors)
Tissue Engineering and Regenerative Medicine
Published: Aug 2014
1 citation
1 citation
3121 days before retraction
Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
Lucas de Sousa Cavalcante, Gisele Monteiro
European Journal of Pharmacology
Published: Jul 2014
525 citations
525 citations
3123 days before retraction
Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies
Yimon Aye, M Li, Marcus J. C. Long et al. (4 authors)
Oncogene
Open Access
Published: Jun 2014
396 citations
396 citations
3174 days before retraction
Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine
Minori Kamada, Kohei Akiyoshi, Nobutake Akiyama et al. (8 authors)
Oncology Reports
Open Access
Published: May 2014
3 citations
3 citations
3184 days before retraction
Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma
Wei Kang, Joanna H. Tong, Anthony W.H. Chan et al. (11 authors)
Oncology Reports
Open Access
Published: Apr 2014
17 citations
17 citations
3221 days before retraction
miR-211 Modulates Gemcitabine Activity Through Downregulation of Ribonucleotide Reductase and Inhibits the Invasive Behavior of Pancreatic Cancer Cells
Mina Maftouh, Amir Avan, Niccola Funel et al. (10 authors)
Nucleosides Nucleotides & Nucleic Acids
Published: Apr 2014
65 citations
65 citations
3240 days before retraction
Design and Synthesis of 4-N-Alkanoyl and 4-N-Alkyl Gemcitabine Analogues Suitable for Positron Emission Tomography
Jesse Pulido
Unknown Journal
Open Access
Published: Mar 2014
4 citations
4 citations
3269 days before retraction
MicroRNA Cancer Therapeutics and the Challenge of Drug Delivery
Steven J. Greco, Jessian L. Munoz, Pranela Rameshwar
Springer eBooks
Published: Jan 2014
2 citations
2 citations
3333 days before retraction
AKT-Induced Tamoxifen Resistance Is Overturned by RRM2 Inhibition
Khyati N. Shah, Kshama Mehta, David Peterson et al. (6 authors)
Molecular Cancer Research
Open Access
Published: Dec 2013
49 citations
49 citations
3344 days before retraction
The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers
Yasheng Huang, Xiyong Liu, Yuan‐Hung Wang et al. (9 authors)
Urologic Oncology Seminars and Original Investigations
Published: Dec 2013
21 citations
21 citations
3346 days before retraction
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
Charlotte L. Tykjaer Jørgensen, Bent Ejlertsen, Karsten Bjerre et al. (6 authors)
BMC Cancer
Open Access
Published: Nov 2013
14 citations
14 citations
3383 days before retraction
Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma
Hua Tian, Chao Ge, Hong Li et al. (11 authors)
Hepatology
Published: Nov 2013
52 citations
52 citations
3386 days before retraction
Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy
Lei Wang, Long Meng, Xingwen Wang et al. (5 authors)
Tumor Biology
Published: Oct 2013
50 citations
50 citations
3403 days before retraction
The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models
Qi Ling, Xiao Xu, Shusen Zheng et al. (4 authors)
Hepatobiliary & pancreatic diseases international
Published: Oct 2013
51 citations
51 citations
3425 days before retraction
<i>IN VIVO</i> IMAGING AND DELIVERY OF siRNA
Zdravka Medarova, Anna Moore
Unknown Journal
Published: Sep 2013
1 citation
1 citation
3436 days before retraction
Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA
Jie Gao, Huaiwen Chen, Yongsheng Yu et al. (12 authors)
Biomaterials
Published: Sep 2013
89 citations
89 citations
3436 days before retraction
Quick Stats
Total Citations:
230
Years Since Retraction:
2.8 years
Open Access:
Yes
Last Checked:
Jul 24, 2025